secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acorda Therapeutics, Inc. (—)
CIK:        0001008848
Form:       8-K
Filed at:   2024-03-13T23:59:59+00:00
Accession:  0000950170-24-030816
Event type: other
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acorda Therapeutics amends Bylaws to enhance director nomination procedures and conform to Delaware law
--------------------------------------------------------------------------------

- Board adopted Amended and Restated Bylaws effective March 7, 2024.
- Enhanced disclosure and procedural requirements for stockholder director nominations, including Rule 14a-19 compliance.
- Updated provisions reflect recent amendments to Delaware General Corporation Law.
- Includes clerical and conforming changes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1008848/000095017024030816/0000950170-24-030816-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1008848/000095017024030816/acor-20240307.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-030816

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer